Volume | 3,037 |
|
|||||
News | - | ||||||
Day High | 28.165 | Low High |
|||||
Day Low | 27.95 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Stevanato Group SpA | STVN | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
27.98 | 27.95 | 28.165 | 27.52 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
24 | 3,037 | $ 27.99 | $ 85,008 | - | 23.00 - 36.30 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
09:49:39 | 10 | $ 28.0677 | USD |
Stevanato Group SpA Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
8.27B | 295.54M | - | 1B | 142.85M | 0.48 | 57.89 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Stevanato News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 28.48 | 28.50 | 26.4708 | 27.06 | 391,734 | -0.42 | -1.47% |
1 Month | 32.35 | 32.98 | 26.4708 | 28.74 | 349,170 | -4.29 | -13.26% |
3 Months | 33.16 | 34.73 | 25.52 | 30.43 | 393,155 | -5.10 | -15.38% |
6 Months | 30.91 | 34.73 | 23.00 | 29.12 | 344,974 | -2.85 | -9.22% |
1 Year | 26.27 | 36.30 | 23.00 | 29.75 | 330,956 | 1.79 | 6.81% |
3 Years | 16.65 | 36.30 | 13.355 | 23.12 | 360,740 | 11.41 | 68.53% |
5 Years | 16.65 | 36.30 | 13.355 | 23.12 | 360,740 | 11.41 | 68.53% |
Stevanato Description
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America. |